EarlyNarratives
Pricing
Start free trialSign in
Start free trialSign in
Today's Brief

Updated daily.

Get the free BIOTECH brief in 5 minutes.

A free daily and weekly email that tells you what changed, what is noise, and where to verify it at the source.

  • Start with the short list before you open another feed.
  • See what is continuing versus what is only today's spike.
  • Open the original sources in one click when you want to verify.
Free daily + weekly email
Read today's brief

Free by email: Today’s Brief (daily) + This Week’s Brief (weekly). Upgrade later for archive, alerts, search, exports, API, and workflow.

Get tomorrow's brief by email

One field, compact consent, daily + weekly by default.

Free by email: Today’s Brief.
Please confirm consent to continue.
Add your email to continue.
How it worksBrowse signals
What you would receive
Preview

Biogen advances tau-targeting Alzheimer's drug despite phase 2 trial setback

Biogen is moving forward with late-stage development of its tau-targeting Alzheimer's drug BIIB080 despite a phase 2 trial missing its primary endpoint.

Why now: Recent phase 2 trial results provide new insights into BIIB080's efficacy and safety profile.

Browse signals
Read today's briefBrowse signals
Today’s strongest item first

Read the strongest BIOTECH shift in minutes before the feed fragments it.

Proof, not boilerplate

3 real source links are already visible in today’s public example.

Free brief before upgrade

Get the daily + weekly brief by email first. Upgrade only if you need archive, alerts, search, exports, API, and deeper workflow tools.

What lands in your free brief

Start with the brief, then drill down only on the items that matter.

Briefing item

Regenxbio’s Duchenne gene therapy meets primary endpoint in pivotal phase 3 trial

Regenxbio has achieved a significant milestone by meeting the primary endpoint in its pivotal phase 3 trial for Duchenne muscular dystrophy gene therapy.

Why now: Regenxbio recently overcame an FDA clinical hold and rejection, making this success timely.

CurrentSource diversity aware
Sources: 3
See details ->
Briefing item

Graph neural networks advance spatial transcriptomics and cancer signaling analysis

Recent developments in graph neural network (GNN) methodologies are enhancing the analysis of complex biological data in spatial transcriptomics and cancer signaling.

Why now: New graph-based methods address noise and sparsity challenges in biological data.

CurrentSource diversity aware
Sources: 3
See details ->
Briefing item

FDA places full clinical hold on Aardvark's phase 3 Prader-Willi syndrome trial

The FDA has imposed a full clinical hold on Aardvark Therapeutics' phase 3 trial for its Prader-Willi syndrome drug due to safety concerns. In response, Aardvark plans to unblind the late-stage study data, a move that could lead to a significant revision of its development program.

Why now: The FDA hold was imposed recently, marking a fresh development in Aardvark's program.

CurrentSource diversity aware
Sources: 2
See details ->
How it works

Built to save you time while keeping every key point easy to verify.

Read widely

News, social, dev channels, and primary sources.

Remove duplicates

Filter rewrites, SEO clones, and repeated takes.

Group what belongs together

So you see one story, not 20 scattered posts.

Deliver the briefing

A daily scan + drill-down with source links.

See Methodology
Start free, upgrade only if you need more

Start with the free brief if you want the signal first, not an hour of scrolling. It gives you the short list, the context, and the source links in one pass.

Upgrade later only if you need memory, alerts, archive, exports, API, and recurring workflow for ongoing research work.

Why people start with the free brief
Daily brief

The 5-minute version of what genuinely changed since yesterday.

Momentum over time

See what is building, peaking, or fading across days and weeks.

Source links included

Jump to the originals when you need to verify a claim fast.

Free daily + weekly emailUpgrade only when you need full drill-down
Get the free brief
See pricingThis Week’s Brief
Product tour

A short walkthrough of the BIOTECH dashboards.